for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dermira Inc

DERM.OQ

Latest Trade

7.53USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

5.25

 - 

15.47

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Dermira Posts Q3 Loss Per Share Of $1.06

Nov 5 (Reuters) - Dermira Inc <DERM.O>::DERMIRA REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 REVENUE $11.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $11.2 MILLION.QTRLY LOSS PER SHARE $1.06.FOR QBREXZA, MANAGEMENT EXPECTS NET PRODUCT SALES FOR FULL YEAR 2019 IN LOW-$30 MILLION RANGE.EXPECTS 2019 RESEARCH AND DEVELOPMENT AND SG&A EXPENSES TO BE BETWEEN $275 & $285 MILLION, INCLUDING ESTIMATED STOCK-BASED COMPENSATION EXPENSE OF ABOUT $30 MILLION.COMPANY WILL RECOGNIZE A $20 MILLION ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE IN Q4 OF 2019.Q3 EARNINGS PER SHARE VIEW $-1.30 -- REFINITIV IBES DATA.

Dermira Announces Initiation Of Phase 3 Program Evaluating Lebrikizumab In Patients With Moderate-To-Severe Atopic Dermatitis

Oct 9 (Reuters) - Dermira Inc <DERM.O>::DERMIRA ANNOUNCES INITIATION OF PHASE 3 PROGRAM EVALUATING LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.DERMIRA INC - TOPLINE RESULTS FROM 16-WEEK INDUCTION PERIOD EXPECTED IN FIRST HALF OF 2021.DERMIRA - TWO IDENTICAL PHASE 3 MONOTHERAPY STUDIES EXPECTED TO ENROLL A TOTAL OF ABOUT 800 ADULT AND ADOLESCENT PATIENTS AGES 12 AND OLDER.

Dermira Says Q2 Revenue of $66.6 Million

Aug 7 (Reuters) - Dermira Inc <DERM.O>::DERMIRA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $66.6 MILLION.Q2 REVENUE ESTIMATE $32 MILLION -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, DERMIRA HAD CASH AND INVESTMENTS OF $327.2 MILLION.FOR QBREXZA, MANAGEMENT EXPECTS NET PRODUCT SALES FOR FULL YEAR 2019 IN LOW-$30 MILLION RANGE.FOR QBREXZA, MANAGEMENT EXPECTS GROSS-TO-NET DISCOUNT FOR SECOND HALF OF YEAR TO REMAIN AT APPROXIMATELY 40 PERCENT.SEES COLLABORATION AND LICENSE REVENUE RELATED TO ALMIRALL AGREEMENT OF APPROXIMATELY $2 MILLION FOR EACH OF THIRD AND FOURTH QUARTERS OF 2019.

Almirall Exercises Its Option With Dermira To License Rights To Lebrikizumab In Europe For Atopic Dermatitis

June 25 (Reuters) - Almirall SA <ALM.MC>::EXERCISES ITS OPTION WITH DERMIRA TO LICENSE RIGHTS TO LEBRIKIZUMAB IN EUROPE FOR ATOPIC DERMATITIS.ESTIMATES POTENTIAL PEAK SALES OF AROUND 450 MILLION EUROS.WILL PAY DERMIRA AN OPTION EXERCISE FEE OF 50 MILLION DOLLARS.

Almirall To Make Decision Regarding Exercise Of Its Lebrikizumab Option By Mid-Year

June 3 (Reuters) - Almirall SA <ALM.MC>::TO MAKE DECISION REGARDING EXERCISE OF OPTION TO EXCLUSIVELY LICENSE RIGHTS TO DEVELOP AND COMMERCIALIZE LEBRIKIZUMAB IN EUROPE BY MID-YEAR.IF ALMIRALL ELECTS TO EXERCISE ITS OPTION, COMPANY WILL PAY DERMIRA AN OPTION EXERCISE FEE OF $50 MILLION.

Dermira Qtrly Loss Per Share $1.49

May 7 (Reuters) - Dermira Inc <DERM.O>::DERMIRA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 REVENUE $2.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.5 MILLION.QTRLY LOSS PER SHARE $1.49.

Dermira Prices $130.0 Million Public Offering Of Common Stock

March 19 (Reuters) - Dermira Inc <DERM.O>::DERMIRA PRICES $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 9.8 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $13.25 PER SHARE.

Dermira Announces Proposed Public Offering Of Common Stock

March 18 (Reuters) - Dermira Inc <DERM.O>::DERMIRA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.DERMIRA INC - INTENDS TO OFFER $110.0 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.DERMIRA INC - ALL OF SHARES WILL BE OFFERED AND SOLD BY DERMIRA.

Dermira Inc Says All Three Doses Of Lebrikizumab Met Primary Endpoint With Statistical Significance

March 18 (Reuters) - Dermira Inc <DERM.O>::DERMIRA ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2B STUDY OF LEBRIKIZUMAB IN PATIENTS WITH ATOPIC DERMATITIS.DERMIRA INC - ALL THREE DOSES OF LEBRIKIZUMAB MET PRIMARY ENDPOINT WITH STATISTICAL SIGNIFICANCE.DERMIRA INC - LEBRIKIZUMAB WAS WELL-TOLERATED; SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES.DERMIRA INC - LEBRIKIZUMAB WAS WELL-TOLERATED; SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES.DERMIRA INC - EFFICACY AND SAFETY PROFILE SUPPORT ADVANCEMENT INTO PHASE 3; PLANNED BY END OF 2019.

Dermira Inc Entered Into First Amendment To License Agreement With Roche

Feb 28 (Reuters) - Dermira Inc <DERM.O>::DERMIRA INC - ENTERED INTO FIRST AMENDMENT TO LICENSE AGREEMENT WITH ROCHE.DERMIRA INC - AMENDMENT AMENDS LICENSE AGREEMENT, DATED AUGUST 8, 2017, BY AND BETWEEN DERMIRA AND ROCHE.DERMIRA INC - AMENDMENT PROVIDES ROCHE WILL SUPPLY DERMIRA WITH UP TO APPROXIMATELY $16 MILLION IN EXISTING LEBRIKIZUMAB DRUG SUBSTANCE, FREE OF CHARGE.DERMIRA- AMENDMENT CUTS CO'S MILESTONE PAYMENT OBLIGATION TO ROCHE IN CONNECTION WITH INITIATION OF PHASE 3 CLINICAL STUDY OF LEBRIKIZUMAB TO $20 MILLION.DERMIRA INC - AMENDMENT REVISES CO'S OBLIGATION TO MAKE ROYALTY PAYMENTS REPRESENTING PERCENTAGES OF TIERS OF ANNUAL NET SALES OF LEBRIKIZUMAB.DERMIRA INC - UNDER AMENDMENT, PERCENTAGES OF TIERS OF ANNUAL NET SALES OF LEBRIKIZUMAB ARE RAISED.DERMIRA - AMENDMENT ELIMINATES CO'S MILESTONE PAYMENT OBLIGATION TO ROCHE UPON SUBMISSION OF FIRST APPLICATION FOR APPROVAL OF LEBRIKIZUMAB IN U.S..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up